Esperança et al. 2026: *Molecules* Scoping Review—Ibogaine Therapeutic Potential, Cardiac Safety & SUD Translation

Definition box

Definition: Monica Patrícia Esperança, Nelson G.M. Gomes, and Maria Graça Campos (2026) published the scoping review *Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives in the Treatment of Substance Use Disorders* in *Molecules* (doi: 10.3390/molecules31030545; *Molecules* 31(3):545). Authors synthesize preclinical and clinical literature on ibogaine for SUD with emphasis on withdrawal/craving signals, dose–response themes, and cardiac adverse events. They frame ibogaine’s multimodal neuropharmacology as scientifically interesting amid high global SUD burden, while stressing fragmented heterogeneous evidence, regulatory gaps, formulation/standardization limits, and unresolved cardiac safety—including hERG/IKr inhibition and QT/QTc prolongation involving ibogaine and long-lived noribogaine. This is a scoping review, not a late-phase efficacy proof, not a cure claim, and not validation of psychoactive IV ibogaine infusion. Ibogaine is U.S. Schedule I and not FDA-approved.

Quotable answer (55 words)

Esperança and colleagues’ 2026 Molecules scoping review finds ibogaine scientifically intriguing for SUD but constrained by fragmented evidence and unresolved cardiac safety—hERG blockade and QTc risk included. A scoping review is not a cure and not proof of psychoactive IV ibogaine infusion. Schedule I; screen for cardiac risk first.

Why this paper-spoke exists

2024–2026 brought new human follow-ups, commentaries, and landscape papers. Families need a current scoping map that refuses to separate “hope” from “heart.” This spoke is that map. Soft CTA: /safety-and-screening → /apply. Pair with sequential-models psychiatry scoping (/blog/updated-scoping-sequential-ibogaine-psychiatry), thirty-year narrative (/blog/thirty-years-ibogaine-research-review), and CV teaching (/blog/ibogaine-cardiovascular-complications-review).

What was reviewed

| Feature | Accurate description | |---------|----------------------| | Citation | Esperança M.P., Gomes N.G.M., Campos M.G. Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives in the Treatment of Substance Use Disorders—A Scoping Review. *Molecules*. 2026;31(3):545. doi 10.3390/molecules31030545 | | Type | Scoping review | | Focus domains | SUD therapeutic potential; withdrawal/craving; dose–response; cardiac AEs; translational constraints | | Cardiac mechanism emphasis | hERG/IKr → reduced repolarization reserve → QT/QTc → TdP substrate; noribogaine contribution | | Translational constraints named | Fragmented evidence; regulatory absence in many jurisdictions; phytochemical validation/standardization limits; cardiac safety unresolved | | What it is not | Pivotal RCT; FDA approval; psychoactive IV brand proof |

Methods (plain language)

Scoping reviews chart the breadth of evidence rather than produce a single pooled effect size for “does it cure addiction?” Expect a structured synthesis of preclinical and clinical sources with explicit attention to where translation fails—especially cardiac risk and standardization. Readers should use this paper to update mental models of uncertainty, not to skip ECG.

Key findings / themes (no hype)

Themes aligned with the published abstract and cardiac-focused discussion:

• Approved SUD medications often hit narrow mechanisms; ibogaine’s multimodal profile (glutamatergic, dopaminergic, cortical/executive-network themes in the authors’ framing) is why researchers keep looking.
• Clinical translation remains blocked by heterogeneous data quality, regulatory patchiness, and formulation/standardization problems.
• Withdrawal and craving signals appear in parts of the literature—but evidence remains insufficient for definitive efficacy conclusions.
• Cardiac adverse events and hERG-linked repolarization delay are central translational constraints, compounded by noribogaine’s prolonged time course.
• Authors discuss a neurobiological “reset” hypothesis as a research framing—hypothesis ≠ proven consumer cure.
• Call to action: rigorous pharmacological, toxicological, and regulatory evaluation for safer standardized pathways.

Honest reading: “Therapeutic potential” in a title is an invitation to research discipline—not a marketing warranty.

How this 2026 scoping review fits the SEO cluster

Place Esperança et al. beside—not above—other honesty documents:

| Cluster neighbor | Relationship | |------------------|--------------| | Sharma sequential psychiatry scoping (/blog/updated-scoping-sequential-ibogaine-psychiatry) | Psychiatry/sequential lens; also “not recommended” clinical stance | | Köck / thirty-year narrative (/blog/thirty-years-ibogaine-research-review) | Long-arc research humility | | Świeczkowski trial landscape (/blog/not-losing-momentum-ibogaine-trials-2025) | Registry momentum ≠ late-phase proof | | MISTIC primary + commentary (/blog/stanford-ibogaine-mistic, /blog/brody-siddiqi-2024-mistic-commentary) | Oral + IV Mg observational hope still needs controlled cardiac science | | Analog/preclinical (/blog/cameron-2020-tabernanthalog, /blog/alper-herg-ibogaine-cardiac-mechanism) | Mechanism and redesign attempts do not erase present ibogaine QT liability |

The review’s insistence on phytochemical validation and formulation standardization also matters for families: “ibogaine” on a label is not a uniform pharmaceutical product in gray-market settings. Purity, dose accuracy, and adulterants remain YMYL confounders even before hERG biology enters the room.

Cardiac / YMYL deep dive (what families should keep)

| Mechanism theme | Practical implication | |-----------------|----------------------| | hERG/IKr block | Demand QTc-aware protocols | | Noribogaine persistence | Monitoring windows may need to outlast parent Tmax folklore | | Concentration-dependent QT risk | Screening + telemetry culture, not vibes | | Polypharmacy / CYP2D6 | Medication review is non-optional (/blog/knuijver-2024-ibogaine-pk-cyp2d6) |

Checklists: /blog/ibogaine-ecg-pre-infusion-checklist, /blog/ibogaine-telemetry-acls-monitoring, /blog/ibogaine-contraindications, /blog/ibogaine-pre-existing-heart-conditions.

Route honesty: scoping SUD literature ≠ IV brand proof

Most human SUD ibogaine evidence remains oral or route-unspecified clinic observation. A 2026 scoping review that catalogs cardiac constraints does not magically become an efficacy RCT for psychoactive intravenous ibogaine. Oral + IV Mg protocols (e.g., MISTIC) still require oral≠IV labeling (/blog/stanford-ibogaine-mistic, /blog/ibogaine-oral-vs-iv). Entity: /what-is-ibogaine-infusion.

Limits and confounders

| Limit | Why it matters | |-------|----------------| | Scoping ≠ definitive meta-analytic efficacy proof | Breadth over pooled certainty | | Heterogeneous primary studies | Observational bias, small N, variable dosing | | Formulation variability | Bark vs HCl vs unknown internet product | | Cardiac risk unresolved | Review cannot “solve” arrhythmia biology | | Schedule I friction | Research ≠ retail access in the U.S. |

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “2026 Molecules review = approved cure” | False | | “Potential = personal guarantee” | False | | “Cardiac chapter means risk is theoretical only” | Dangerously false | | Cite as current SUD + cardiac-safety scoping map? | Yes |

No cure claims.

Soft CTA

If a 2026 review’s “potential” language feels like permission, re-read the cardiac chapter. Then use /safety-and-screening and /apply only for physician-supervised IV ibogaine infusion exploration with screening literacy. Entity: /what-is-ibogaine-infusion.

FAQ

What is the Molecules 2026 ibogaine paper? A scoping review by Esperança, Gomes, and Campos on therapeutic potential, cardiac safety, and SUD translational perspectives (doi **10.3390/molecules31030545**).

Does it prove ibogaine cures addiction? No—scoping synthesis of fragmented evidence; no cure claims.

What cardiac mechanism do they emphasize? hERG/IKr inhibition with QT/QTc prolongation risk, including noribogaine’s contribution.

Is this about IV ibogaine infusion? No—it scopes SUD literature that is not brand-IV proof.

Are regulatory frameworks settled globally? No—authors highlight regulatory gaps and standardization limits.

Is ibogaine FDA-approved? No. Schedule I; not FDA-approved.

Should families still insist on ECG/telemetry? Yes.

Where should screening start? /safety-and-screening, then /apply if appropriate.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Esperança et al. 2026 is a scoping review—not personal access, not a cure claim, and not psychoactive IV ibogaine efficacy proof.

Sources (selected)

1. Esperança M.P., Gomes N.G.M., Campos M.G. Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives… *Molecules*. 2026;31(3):545. doi: 10.3390/molecules31030545.
2. Litjens R.P.W., Brunt T.M. *Clin Toxicol*. 2016. doi: 10.3109/15563650.2016.1138226.
3. Alper K. et al. *Cardiovasc Toxicol*. 2016. doi: 10.1007/s12012-015-9311-5.
4. Brunt T.M. *Addiction*. 2026. doi: 10.1111/add.70319.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).